Multimodal Prognostic System for Heart Failure: A Multi-Center Study
ConditionHeart Failure
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorChongqing Medical University
About this trial
This study is a multicenter retrospective research aimed at developing a heart failure prognosis warning system based on multimodal clinical data to improve the diagnosis and treatment of heart failure.
This study aims to address the following main questions:
1. What are the clinical characteristics and current treatment status of heart failure patients? 2. What factors influence the onset of heart failure and the prognosis of patients? 3. How can real-world big data be utilized to construct an accurate heart failure prognosis assessment model? 4. How can this prognosis assessment model help improve the therapeutic effects and quality of life for heart failure patients?
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
None
Disqualifiers
None
Trial population
The study population for this research consists of adult patients, aged 18 and above, with a discharge diagnosis of heart failure between January 2011 and December 2024, as per the guidelines for the diagnosis and treatment of heart failure . The patients' electronic medical records, which include demographic information, comorbidities, treatment plans, and various clinical indicators, are sourced , ensuring a comprehensive and in-depth analysis of the heart failure patient cohort.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
In-hospital mortality or other adverse outcomes, including readmission, in-hospital infection, respiratory failure, liver failure, and renal failure.
The study focuses on evaluating the risk factors and predictors of in-hospital mortality and various adverse outcomes in heart failure patients, encompassing events such as readmission due to exacerbation of the condition, infections acquired during hospital stay, critical impairments in respiratory, liver, and kidney functions that may complicate the clinical course and impact patient prognosis.
Time frame
Evaluations will be conducted within 30, 60, or 90 days post-admission for heart failure patients to assess the impact of the condition and the effectiveness of treatment.Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: